Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study
Abstract Background: Pregabalin and gabapentin are marketed to treat peripheral neuropathic pain, but head-to-head comparison is lacking. Objectives: The aims of this work were to compare the effects of pregabalin and gabapentin on different patient-reported health outcomes and to analyze health car...
Gespeichert in:
| Veröffentlicht in: | Clinical therapeutics 2010-07, Vol.32 (7), p.1357-1370 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1370 |
|---|---|
| container_issue | 7 |
| container_start_page | 1357 |
| container_title | Clinical therapeutics |
| container_volume | 32 |
| creator | Pérez, Concepción, MD, PhD Navarro, Ana, MD, PhD Saldaña, María T., MD, PhD Masramón, Xavier, BSc Rejas, Javier, MD, PhD |
| description | Abstract Background: Pregabalin and gabapentin are marketed to treat peripheral neuropathic pain, but head-to-head comparison is lacking. Objectives: The aims of this work were to compare the effects of pregabalin and gabapentin on different patient-reported health outcomes and to analyze health care and nonhealth-care resource consumption and their related costs among patients treated for peripheral neuropathic pain in primary medical care. Methods: A cost-consequences comparison in subjects with refractory (suboptimal response to ≥1 previous analgesic treatment for >6 months) chronic peripheral neuropathic pain was carried out using data extracted from two 12-week, observational, prospective studies in primary medical care. Patients were eligible if they were aged ≥18 years, had a score of ≥4 on the Douleur Neuropathique 4 questionnaire, and were able to complete health questionnaires written in Spanish. A nested-paired case-control design was chosen to perform the comparison with 2 controls (pregabalin) per case (gabapentin) matched by age, sex, peripheral neuropathic pain condition, time since diagnosis, number of previous treatments, pain intensity, depressive and anxiety symptom scores, and health state. Adult subjects with refractory chronic pain because of diabetic neuropathy, postherpetic or trigeminal neuralgias, or cervical or lumbosacral radiculopathies were included. Epidemiologic statistical methods were applied for comparing health effects (pain intensity, sleep, anxiety and depressive symptoms, disability, and health state), resources utilization, and related cost variations after 12 weeks. Indirect costs were measured by means of lost-workday equivalent calculations multiplied by the mean national daily salary. Results: Analysis included 44 patients treated with gabapentin (cases) and 88 patients treated with pregabalin (controls) who were matched for age, sex, and other parameters. The mean (SD) gabapentin and pregabalin doses were 1263 (540) and 202 (119) mg/d, respectively. Although there was a greater reduction in last-week mean pain intensity with pregabalin (visual analog scale: 39.1 [22.5] vs 28.0 [22.2] mm; P = 0.008), as well as more patients with a ≥50% reduction in pain rate (60.9% vs 40.5%; P = 0.029), there were no significant differences between groups for sensory, affective, total, or present pain intensity. The significantly higher drug cost associated with pregabalin was offset by a greater reduction in productivity costs |
| doi_str_mv | 10.1016/j.clinthera.2010.07.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_748939334</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0149291810002419</els_id><sourcerecordid>2734243051</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-56937ef821fe7797c5936a7378b148986e3c0bbe73b2a321984be6bf90994d493</originalsourceid><addsrcrecordid>eNqNklGL1DAQx4so3nn6FTQg4lPXpOk2jQ_CcXgqHCio4FtI0-lt1m7Ty6TKfkq_khN2vYN7EgpNJr_5ZzL_KYoXgq8EF82b7cqNfkobiHZVcYpyteKiflCcilbpUoj6x8PilCK6rLRoT4oniFvOudTr6nFxUvFGtU0rT4s_XyJc286SGrNTz_J6hinRlr6dTW4DPZtt8hRE9tunDZsh-jlfPbIJlhjodOMdQYekGBZKB7aD3jti5mhd8g7ymaWd39m4Z85GYAiJ0Ou37NJPPS2QDTHsiHIBU-nChHCzwOQAqTg77tHjQWUCTFSXswgZSzGMDNPS758WjwY7Ijw7_s-K75fvv118LK8-f_h0cX5VujVvU7lutFQwtJUYQCmt3FrLxiqp2k7UrW4bkI53HSjZVVZWQrd1B003aK513ddanhWvD7pzDFQiJrPz6GAc7QRhQaNIRWopayJf3iO3YYn0GjSCSynWpCiJUgfKxYAYYTDHRhFksuVma24tN9lyw5Uhgynz-VF_6ajlt3n_PCbg1RGwSH4M0U7O4x0nSUTwhrjzAwfUt18eokHnc_N7H8El0wf_H8W8u6eRuTwGP2EPePdyg5Xh5mue0DyggmazqoWWfwH05uce</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1033159943</pqid></control><display><type>article</type><title>Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Pérez, Concepción, MD, PhD ; Navarro, Ana, MD, PhD ; Saldaña, María T., MD, PhD ; Masramón, Xavier, BSc ; Rejas, Javier, MD, PhD</creator><creatorcontrib>Pérez, Concepción, MD, PhD ; Navarro, Ana, MD, PhD ; Saldaña, María T., MD, PhD ; Masramón, Xavier, BSc ; Rejas, Javier, MD, PhD</creatorcontrib><description>Abstract Background: Pregabalin and gabapentin are marketed to treat peripheral neuropathic pain, but head-to-head comparison is lacking. Objectives: The aims of this work were to compare the effects of pregabalin and gabapentin on different patient-reported health outcomes and to analyze health care and nonhealth-care resource consumption and their related costs among patients treated for peripheral neuropathic pain in primary medical care. Methods: A cost-consequences comparison in subjects with refractory (suboptimal response to ≥1 previous analgesic treatment for >6 months) chronic peripheral neuropathic pain was carried out using data extracted from two 12-week, observational, prospective studies in primary medical care. Patients were eligible if they were aged ≥18 years, had a score of ≥4 on the Douleur Neuropathique 4 questionnaire, and were able to complete health questionnaires written in Spanish. A nested-paired case-control design was chosen to perform the comparison with 2 controls (pregabalin) per case (gabapentin) matched by age, sex, peripheral neuropathic pain condition, time since diagnosis, number of previous treatments, pain intensity, depressive and anxiety symptom scores, and health state. Adult subjects with refractory chronic pain because of diabetic neuropathy, postherpetic or trigeminal neuralgias, or cervical or lumbosacral radiculopathies were included. Epidemiologic statistical methods were applied for comparing health effects (pain intensity, sleep, anxiety and depressive symptoms, disability, and health state), resources utilization, and related cost variations after 12 weeks. Indirect costs were measured by means of lost-workday equivalent calculations multiplied by the mean national daily salary. Results: Analysis included 44 patients treated with gabapentin (cases) and 88 patients treated with pregabalin (controls) who were matched for age, sex, and other parameters. The mean (SD) gabapentin and pregabalin doses were 1263 (540) and 202 (119) mg/d, respectively. Although there was a greater reduction in last-week mean pain intensity with pregabalin (visual analog scale: 39.1 [22.5] vs 28.0 [22.2] mm; P = 0.008), as well as more patients with a ≥50% reduction in pain rate (60.9% vs 40.5%; P = 0.029), there were no significant differences between groups for sensory, affective, total, or present pain intensity. The significantly higher drug cost associated with pregabalin was offset by a greater reduction in productivity costs compared with gabapentin, yielding similar cost reduction (−€1254 [1479] vs −€1384 [2874], respectively; P = NS). Conclusion: Pregabalin appeared to be associated with greater reduction in mean weekly intensity of pain, but there were no significant differences in cost.</description><identifier>ISSN: 0149-2918</identifier><identifier>EISSN: 1879-114X</identifier><identifier>DOI: 10.1016/j.clinthera.2010.07.014</identifier><identifier>PMID: 20678683</identifier><language>eng</language><publisher>Bridgewater, NJ: EM Inc USA</publisher><subject>Aged ; Amines - administration & dosage ; Amines - economics ; Amines - therapeutic use ; Analgesics - administration & dosage ; Analgesics - economics ; Analgesics - therapeutic use ; Anxiety ; Biological and medical sciences ; Case-Control Studies ; Chronic pain ; Clinical Trials as Topic ; Cost analysis ; costs ; Cranial nerves. Spinal roots. Peripheral nerves. Autonomic nervous system. Gustation. Olfaction ; Cyclohexanecarboxylic Acids - administration & dosage ; Cyclohexanecarboxylic Acids - economics ; Cyclohexanecarboxylic Acids - therapeutic use ; Diabetes ; Diabetic neuropathy ; Drug Costs ; Efficiency ; Female ; gabapentin ; gamma-Aminobutyric Acid - administration & dosage ; gamma-Aminobutyric Acid - analogs & derivatives ; gamma-Aminobutyric Acid - economics ; gamma-Aminobutyric Acid - therapeutic use ; head-to-head comparison ; Health Care Costs ; Humans ; Internal Medicine ; Male ; Medical Education ; Medical practices ; Medical sciences ; Mental depression ; Middle Aged ; Migraine ; Nervous system (semeiology, syndromes) ; Neurology ; neuropathic pain ; Pain Measurement ; patient-reported outcomes ; Patients ; Peripheral Nervous System Diseases - drug therapy ; Peripheral Nervous System Diseases - economics ; Peripheral neuropathy ; Pharmacology. Drug treatments ; Pregabalin ; Primary care ; Primary Health Care ; Quality of life ; Questionnaires ; Sleep ; therapeutic dose</subject><ispartof>Clinical therapeutics, 2010-07, Vol.32 (7), p.1357-1370</ispartof><rights>Excerpta Medica Inc.</rights><rights>2010 Excerpta Medica Inc.</rights><rights>2015 INIST-CNRS</rights><rights>2010 Excerpta Medica Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-56937ef821fe7797c5936a7378b148986e3c0bbe73b2a321984be6bf90994d493</citedby><cites>FETCH-LOGICAL-c508t-56937ef821fe7797c5936a7378b148986e3c0bbe73b2a321984be6bf90994d493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0149291810002419$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23143106$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20678683$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pérez, Concepción, MD, PhD</creatorcontrib><creatorcontrib>Navarro, Ana, MD, PhD</creatorcontrib><creatorcontrib>Saldaña, María T., MD, PhD</creatorcontrib><creatorcontrib>Masramón, Xavier, BSc</creatorcontrib><creatorcontrib>Rejas, Javier, MD, PhD</creatorcontrib><title>Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study</title><title>Clinical therapeutics</title><addtitle>Clin Ther</addtitle><description>Abstract Background: Pregabalin and gabapentin are marketed to treat peripheral neuropathic pain, but head-to-head comparison is lacking. Objectives: The aims of this work were to compare the effects of pregabalin and gabapentin on different patient-reported health outcomes and to analyze health care and nonhealth-care resource consumption and their related costs among patients treated for peripheral neuropathic pain in primary medical care. Methods: A cost-consequences comparison in subjects with refractory (suboptimal response to ≥1 previous analgesic treatment for >6 months) chronic peripheral neuropathic pain was carried out using data extracted from two 12-week, observational, prospective studies in primary medical care. Patients were eligible if they were aged ≥18 years, had a score of ≥4 on the Douleur Neuropathique 4 questionnaire, and were able to complete health questionnaires written in Spanish. A nested-paired case-control design was chosen to perform the comparison with 2 controls (pregabalin) per case (gabapentin) matched by age, sex, peripheral neuropathic pain condition, time since diagnosis, number of previous treatments, pain intensity, depressive and anxiety symptom scores, and health state. Adult subjects with refractory chronic pain because of diabetic neuropathy, postherpetic or trigeminal neuralgias, or cervical or lumbosacral radiculopathies were included. Epidemiologic statistical methods were applied for comparing health effects (pain intensity, sleep, anxiety and depressive symptoms, disability, and health state), resources utilization, and related cost variations after 12 weeks. Indirect costs were measured by means of lost-workday equivalent calculations multiplied by the mean national daily salary. Results: Analysis included 44 patients treated with gabapentin (cases) and 88 patients treated with pregabalin (controls) who were matched for age, sex, and other parameters. The mean (SD) gabapentin and pregabalin doses were 1263 (540) and 202 (119) mg/d, respectively. Although there was a greater reduction in last-week mean pain intensity with pregabalin (visual analog scale: 39.1 [22.5] vs 28.0 [22.2] mm; P = 0.008), as well as more patients with a ≥50% reduction in pain rate (60.9% vs 40.5%; P = 0.029), there were no significant differences between groups for sensory, affective, total, or present pain intensity. The significantly higher drug cost associated with pregabalin was offset by a greater reduction in productivity costs compared with gabapentin, yielding similar cost reduction (−€1254 [1479] vs −€1384 [2874], respectively; P = NS). Conclusion: Pregabalin appeared to be associated with greater reduction in mean weekly intensity of pain, but there were no significant differences in cost.</description><subject>Aged</subject><subject>Amines - administration & dosage</subject><subject>Amines - economics</subject><subject>Amines - therapeutic use</subject><subject>Analgesics - administration & dosage</subject><subject>Analgesics - economics</subject><subject>Analgesics - therapeutic use</subject><subject>Anxiety</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Chronic pain</subject><subject>Clinical Trials as Topic</subject><subject>Cost analysis</subject><subject>costs</subject><subject>Cranial nerves. Spinal roots. Peripheral nerves. Autonomic nervous system. Gustation. Olfaction</subject><subject>Cyclohexanecarboxylic Acids - administration & dosage</subject><subject>Cyclohexanecarboxylic Acids - economics</subject><subject>Cyclohexanecarboxylic Acids - therapeutic use</subject><subject>Diabetes</subject><subject>Diabetic neuropathy</subject><subject>Drug Costs</subject><subject>Efficiency</subject><subject>Female</subject><subject>gabapentin</subject><subject>gamma-Aminobutyric Acid - administration & dosage</subject><subject>gamma-Aminobutyric Acid - analogs & derivatives</subject><subject>gamma-Aminobutyric Acid - economics</subject><subject>gamma-Aminobutyric Acid - therapeutic use</subject><subject>head-to-head comparison</subject><subject>Health Care Costs</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medical Education</subject><subject>Medical practices</subject><subject>Medical sciences</subject><subject>Mental depression</subject><subject>Middle Aged</subject><subject>Migraine</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Neurology</subject><subject>neuropathic pain</subject><subject>Pain Measurement</subject><subject>patient-reported outcomes</subject><subject>Patients</subject><subject>Peripheral Nervous System Diseases - drug therapy</subject><subject>Peripheral Nervous System Diseases - economics</subject><subject>Peripheral neuropathy</subject><subject>Pharmacology. Drug treatments</subject><subject>Pregabalin</subject><subject>Primary care</subject><subject>Primary Health Care</subject><subject>Quality of life</subject><subject>Questionnaires</subject><subject>Sleep</subject><subject>therapeutic dose</subject><issn>0149-2918</issn><issn>1879-114X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNklGL1DAQx4so3nn6FTQg4lPXpOk2jQ_CcXgqHCio4FtI0-lt1m7Ty6TKfkq_khN2vYN7EgpNJr_5ZzL_KYoXgq8EF82b7cqNfkobiHZVcYpyteKiflCcilbpUoj6x8PilCK6rLRoT4oniFvOudTr6nFxUvFGtU0rT4s_XyJc286SGrNTz_J6hinRlr6dTW4DPZtt8hRE9tunDZsh-jlfPbIJlhjodOMdQYekGBZKB7aD3jti5mhd8g7ymaWd39m4Z85GYAiJ0Ou37NJPPS2QDTHsiHIBU-nChHCzwOQAqTg77tHjQWUCTFSXswgZSzGMDNPS758WjwY7Ijw7_s-K75fvv118LK8-f_h0cX5VujVvU7lutFQwtJUYQCmt3FrLxiqp2k7UrW4bkI53HSjZVVZWQrd1B003aK513ddanhWvD7pzDFQiJrPz6GAc7QRhQaNIRWopayJf3iO3YYn0GjSCSynWpCiJUgfKxYAYYTDHRhFksuVma24tN9lyw5Uhgynz-VF_6ajlt3n_PCbg1RGwSH4M0U7O4x0nSUTwhrjzAwfUt18eokHnc_N7H8El0wf_H8W8u6eRuTwGP2EPePdyg5Xh5mue0DyggmazqoWWfwH05uce</recordid><startdate>20100701</startdate><enddate>20100701</enddate><creator>Pérez, Concepción, MD, PhD</creator><creator>Navarro, Ana, MD, PhD</creator><creator>Saldaña, María T., MD, PhD</creator><creator>Masramón, Xavier, BSc</creator><creator>Rejas, Javier, MD, PhD</creator><general>EM Inc USA</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20100701</creationdate><title>Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study</title><author>Pérez, Concepción, MD, PhD ; Navarro, Ana, MD, PhD ; Saldaña, María T., MD, PhD ; Masramón, Xavier, BSc ; Rejas, Javier, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-56937ef821fe7797c5936a7378b148986e3c0bbe73b2a321984be6bf90994d493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Amines - administration & dosage</topic><topic>Amines - economics</topic><topic>Amines - therapeutic use</topic><topic>Analgesics - administration & dosage</topic><topic>Analgesics - economics</topic><topic>Analgesics - therapeutic use</topic><topic>Anxiety</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Chronic pain</topic><topic>Clinical Trials as Topic</topic><topic>Cost analysis</topic><topic>costs</topic><topic>Cranial nerves. Spinal roots. Peripheral nerves. Autonomic nervous system. Gustation. Olfaction</topic><topic>Cyclohexanecarboxylic Acids - administration & dosage</topic><topic>Cyclohexanecarboxylic Acids - economics</topic><topic>Cyclohexanecarboxylic Acids - therapeutic use</topic><topic>Diabetes</topic><topic>Diabetic neuropathy</topic><topic>Drug Costs</topic><topic>Efficiency</topic><topic>Female</topic><topic>gabapentin</topic><topic>gamma-Aminobutyric Acid - administration & dosage</topic><topic>gamma-Aminobutyric Acid - analogs & derivatives</topic><topic>gamma-Aminobutyric Acid - economics</topic><topic>gamma-Aminobutyric Acid - therapeutic use</topic><topic>head-to-head comparison</topic><topic>Health Care Costs</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medical Education</topic><topic>Medical practices</topic><topic>Medical sciences</topic><topic>Mental depression</topic><topic>Middle Aged</topic><topic>Migraine</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Neurology</topic><topic>neuropathic pain</topic><topic>Pain Measurement</topic><topic>patient-reported outcomes</topic><topic>Patients</topic><topic>Peripheral Nervous System Diseases - drug therapy</topic><topic>Peripheral Nervous System Diseases - economics</topic><topic>Peripheral neuropathy</topic><topic>Pharmacology. Drug treatments</topic><topic>Pregabalin</topic><topic>Primary care</topic><topic>Primary Health Care</topic><topic>Quality of life</topic><topic>Questionnaires</topic><topic>Sleep</topic><topic>therapeutic dose</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pérez, Concepción, MD, PhD</creatorcontrib><creatorcontrib>Navarro, Ana, MD, PhD</creatorcontrib><creatorcontrib>Saldaña, María T., MD, PhD</creatorcontrib><creatorcontrib>Masramón, Xavier, BSc</creatorcontrib><creatorcontrib>Rejas, Javier, MD, PhD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest_Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pérez, Concepción, MD, PhD</au><au>Navarro, Ana, MD, PhD</au><au>Saldaña, María T., MD, PhD</au><au>Masramón, Xavier, BSc</au><au>Rejas, Javier, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study</atitle><jtitle>Clinical therapeutics</jtitle><addtitle>Clin Ther</addtitle><date>2010-07-01</date><risdate>2010</risdate><volume>32</volume><issue>7</issue><spage>1357</spage><epage>1370</epage><pages>1357-1370</pages><issn>0149-2918</issn><eissn>1879-114X</eissn><abstract>Abstract Background: Pregabalin and gabapentin are marketed to treat peripheral neuropathic pain, but head-to-head comparison is lacking. Objectives: The aims of this work were to compare the effects of pregabalin and gabapentin on different patient-reported health outcomes and to analyze health care and nonhealth-care resource consumption and their related costs among patients treated for peripheral neuropathic pain in primary medical care. Methods: A cost-consequences comparison in subjects with refractory (suboptimal response to ≥1 previous analgesic treatment for >6 months) chronic peripheral neuropathic pain was carried out using data extracted from two 12-week, observational, prospective studies in primary medical care. Patients were eligible if they were aged ≥18 years, had a score of ≥4 on the Douleur Neuropathique 4 questionnaire, and were able to complete health questionnaires written in Spanish. A nested-paired case-control design was chosen to perform the comparison with 2 controls (pregabalin) per case (gabapentin) matched by age, sex, peripheral neuropathic pain condition, time since diagnosis, number of previous treatments, pain intensity, depressive and anxiety symptom scores, and health state. Adult subjects with refractory chronic pain because of diabetic neuropathy, postherpetic or trigeminal neuralgias, or cervical or lumbosacral radiculopathies were included. Epidemiologic statistical methods were applied for comparing health effects (pain intensity, sleep, anxiety and depressive symptoms, disability, and health state), resources utilization, and related cost variations after 12 weeks. Indirect costs were measured by means of lost-workday equivalent calculations multiplied by the mean national daily salary. Results: Analysis included 44 patients treated with gabapentin (cases) and 88 patients treated with pregabalin (controls) who were matched for age, sex, and other parameters. The mean (SD) gabapentin and pregabalin doses were 1263 (540) and 202 (119) mg/d, respectively. Although there was a greater reduction in last-week mean pain intensity with pregabalin (visual analog scale: 39.1 [22.5] vs 28.0 [22.2] mm; P = 0.008), as well as more patients with a ≥50% reduction in pain rate (60.9% vs 40.5%; P = 0.029), there were no significant differences between groups for sensory, affective, total, or present pain intensity. The significantly higher drug cost associated with pregabalin was offset by a greater reduction in productivity costs compared with gabapentin, yielding similar cost reduction (−€1254 [1479] vs −€1384 [2874], respectively; P = NS). Conclusion: Pregabalin appeared to be associated with greater reduction in mean weekly intensity of pain, but there were no significant differences in cost.</abstract><cop>Bridgewater, NJ</cop><pub>EM Inc USA</pub><pmid>20678683</pmid><doi>10.1016/j.clinthera.2010.07.014</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-2918 |
| ispartof | Clinical therapeutics, 2010-07, Vol.32 (7), p.1357-1370 |
| issn | 0149-2918 1879-114X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_748939334 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Aged Amines - administration & dosage Amines - economics Amines - therapeutic use Analgesics - administration & dosage Analgesics - economics Analgesics - therapeutic use Anxiety Biological and medical sciences Case-Control Studies Chronic pain Clinical Trials as Topic Cost analysis costs Cranial nerves. Spinal roots. Peripheral nerves. Autonomic nervous system. Gustation. Olfaction Cyclohexanecarboxylic Acids - administration & dosage Cyclohexanecarboxylic Acids - economics Cyclohexanecarboxylic Acids - therapeutic use Diabetes Diabetic neuropathy Drug Costs Efficiency Female gabapentin gamma-Aminobutyric Acid - administration & dosage gamma-Aminobutyric Acid - analogs & derivatives gamma-Aminobutyric Acid - economics gamma-Aminobutyric Acid - therapeutic use head-to-head comparison Health Care Costs Humans Internal Medicine Male Medical Education Medical practices Medical sciences Mental depression Middle Aged Migraine Nervous system (semeiology, syndromes) Neurology neuropathic pain Pain Measurement patient-reported outcomes Patients Peripheral Nervous System Diseases - drug therapy Peripheral Nervous System Diseases - economics Peripheral neuropathy Pharmacology. Drug treatments Pregabalin Primary care Primary Health Care Quality of life Questionnaires Sleep therapeutic dose |
| title | Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T15%3A29%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pregabalin%20and%20gabapentin%20in%20matched%20patients%20with%20peripheral%20neuropathic%20pain%20in%20routine%20medical%20practice%20in%20a%20primary%20care%20setting:%20Findings%20from%20a%20cost-consequences%20analysis%20in%20a%20nested%20case-control%20study&rft.jtitle=Clinical%20therapeutics&rft.au=P%C3%A9rez,%20Concepci%C3%B3n,%20MD,%20PhD&rft.date=2010-07-01&rft.volume=32&rft.issue=7&rft.spage=1357&rft.epage=1370&rft.pages=1357-1370&rft.issn=0149-2918&rft.eissn=1879-114X&rft_id=info:doi/10.1016/j.clinthera.2010.07.014&rft_dat=%3Cproquest_cross%3E2734243051%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1033159943&rft_id=info:pmid/20678683&rft_els_id=S0149291810002419&rfr_iscdi=true |